top of page


Peter Nordkild, MD, CEO

Peter Nordkild is a Medical Doctor from University of Copenhagen (1982).

Dr Nordkild is a co founder of Adenium Biotech ApS, a Danish biotech company focusing on multidrug resistant bacteria and co founder and CEO of ARTS Biologics A/S, a Danish biotech company focusing on improved gonadotrophins for fertility treatment from 2011 till the end of 2012. Previously he was the CEO of Egalet A/S, a Danish biotech company focusing on drug abuse resistant opioids from 2007 till 2010. In 2007 Dr. Nordkild was CCO and CFO at Pharmexa A/S, a Danish biotech company specializing in active immunotherapy for cancer and chronic diseases. From 2000 Dr. Nordkild was employed as Senior Vice President, Commercial Operations in Ferring Pharmaceuticals. Primary responsibilities were expansion and growth of Ferring’s operations with a particular focus on Japan, Eastern Europe and the Middle East. During the previous 12 years, Dr. Nordkild held a number of different clinical development and commercial positions within Novo Nordisk. Initially employed as Medical Director of Squibb-Novo in 1987 and lastly as General Manager Novo Nordisk Austria. Dr. Nordkild is an orthopedic surgeon by training.


He received his training at the University Hospitals of Copenhagen and has published a number of peer reviewed articles primarily within the area of wound healing and intestinal anastomosis and bone fractures. Member of the Board of Directors at Oracain ApS, Asarina pharma ApS, and Dansk Biotek.

Ejner Bech Jensen, MSc

Mr Jensen is head of Novozymes research organization on a global scale. Novozymes A/S develops biological solutions that enable the transformation from a petrochemical to a bio based society. Novozymes works with all aspects of modern biotechnology and are embracing the most advanced technologies that supports enzyme discovery, metabolic engineering and recombinant production of proteins. The organization has 5 different sites and approximately 450 employees worldwide.


Mr Jensen is responsible for technology development and research strategies covering many biotechnology disciplins mainly focusing on industrial biotech, but a part of the organization works in the biopharmaceutical field. This includes anti infectives, human defensins and technologies for improved functionalities such as albumin fusion. Currently we only focus on these enabling technologies that can be used to improve existing biopharmaceuticals and not new drug discovery.


Mr Jensen has worked more than 25 years in the Novo family of companies. Prior to Novozymes Mr Jensen worked in Nordisk Gentofte (hGH, Insulin, different growth factors), and later in Novo Nordisk. Mr Jensen became Director of Molecular Biotechnology in 1995 but returned to California as the President of the R&D group in 2006. Main focus here is molecular biology, metabolic engineering to produce chemicals and cellulosic biofuel.

Søren Neve, PhD

Søren Neve was until 2011 project director for the Arenicin-3 discovery activities in Novozymes A/S. Prior to Novozymes Dr Neve worked in both biotech companies and companies in the pharmaceutical industry with focus on developing novel peptide based pharmaceuticals.


Dr Neve holds a PhD in Protein Chemistry from University of Odense and has authored or co-authored more than 20 patent applications and scientific publications in the field of molecular biology and protein engineering. Dr Neve is director of pharmacology with Orphazyme


Prof. Dr. Jan Wehkamp studied Medicine in Lübeck. Following several research stays in the USA and Germany as a student, post-doc, and later as a faculty member of the University of California, he returned to German to work at the Dr. Margarete Fischer Bosch Institute for Clinical Pharmacology, and the Robert Bosch Hospital in Stuttgart (Germany), where from 2007 till 2012, beside receiving his clinical training, he led an DFG- Emmy Noether Junior Research Group. A specialist in Clinical Pharmacology and a specialist in Internal Medicine and Gastroenterology. 

In 2014 he was appointed to a prestigous Heisenberg professorial post at the Tübingen University Clinic. He is a European Reseach Council starting grantee and also funded by Deutsche Forschungsgemeinschaft. Jan Wehkamp started working on defensins as a medical student in 1997 and still works on the same topic. Together with colleques he helped to establish the new field of innate host defense in translational modern gastroenterology.  


His main current research interest lies in translating these newly gained insights of relevance for the body’s immune barrier into applied therapy.

Jan Wehkamp, MD



Matt Cooper, PhD

Prof. Matt Cooper completed his PhD in 1994 and then spent 13 years in the UK, first at the University of Cambridge, then 9 years in start-ups and biotechnology companies. He returned to Australia in 2009 as a NHMRC Australia Fellow, at the University of Queensland, where he is driving research and development of infectious and inflammatory disease diagnostics and therapeutics. He was founder and Managing Director of Cambridge Medical Innovations (part of Alere Inc.) and CSO and co-founder of Akubio, and co-founder of Defensin Therapeutics.  He has more than 200 scientific articles, 2 books, 22 patents, and has helped launch multiple medical technology products on the market today.

Prof Cooper is a cofounder and CEO of Inflazome ltd. developing inflammasome inhibitors for chronic inflammatory diseases.

bottom of page